Hara Levy

Hara Levy

Auto-generated profile, based on publicly available information

Hara Levy

Department of Pediatrics, Section of Pulmonary and Sleep Medicine

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2008 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
HLHara Levy
Hara Levy
LKLeslie A. Kalish
Leslie A. Kalish
CCCarolyn Cannon
Carolyn Cannon
KGK. Christopher García
K. Christopher García
CGCraig Gerard
Craig Gerard
ACA.A. Colin
A.A. Colin

8 May 2009 in Pediatric Pulmonology
Verified
Journal Article
Open access
PDF file
HLHara Levy
Hara Levy
AMAmy Murphy
Amy Murphy
FZFei Zou
Fei Zou
CGCraig Gerard
Craig Gerard
BKBarbara Klanderman
Barbara Klanderman
SWScott T. Weiss
Scott T. Weiss
Rationale: Variability in pulmonary disease severity is found in patients with cystic fibrosis (CF) who have identical mutations in the CF transmembrane conductance regulator (CFTR) gene. We hypothesized that one factor accounting for heterogeneity in pulmonary disease severity is variation in the family of genes affecting the biology of interleukin‐1 (IL‐1), which impacts acquisition and maintenance of Pseudomonas aeruginosa infection in animal models of chronic infection.Methods: We genotyped 58 single nucleotide polymorphisms (SNPs) in the IL‐1 gene cluster in 808 CF subjects from the University of North Carolina and Case Western Reserve University (UNC/CWRU) joint cohort. All were homozygous for ΔF508, and categories of “severe” (cases) or “mild” (control subjects) lung disease were defined by the lowest or highest quartile of forced expired volume (FEV1) for age in the CF population. After adjustment for age and gender, genotypic data were tested for association with lung disease severity. Odds ratios (ORs) comparing severe versus mild CF were also calculated for each genotype (with the homozygote major allele as the reference group) for all 58 SNPs. From these analyses, nine SNPs with a moderate effect size, OR ≤0.5 or >1.5, were selected for further testing. To replicate the case‐control study results, we genotyped the same nine SNPs in a second population of CF parent–offspring trios (recruited from Children's Hospital Boston), in which the offspring had similar pulmonary phenotypes. For the trio analysis, both family‐based and population‐based associations were performed.Results: SNPs rs1143634 and rs1143639 in the IL1B gene demonstrated a consistent association with lung disease severity categories (P < 0.10) and longitudinal analysis of lung disease severity (P < 0.10) in CF in both the case‐control and family‐based studies. In females, there was a consistent association (false discovery rate adjusted joint P‐value <0.06 for both SNPs) in both the analysis of lung disease severity in the UNC/CWRU cohort and the family‐based analysis of affection status.Conclusion: Our findings suggest that IL1β is a clinically relevant modulator of CF lung disease. Pediatr Pulmonol. 2009; 44:580–593.

1 January 2014 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
HLHara Levy
Hara Levy
MRMelissa Reske
Melissa Reske
RBRachel Bersie
Rachel Bersie
JBJoseph Barbieri
Joseph Barbieri
SJShuang Jia
Shuang Jia
MHMartin J. Hessner
Martin J. Hessner

26 April 2010 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
HLHara Levy
Hara Levy
CCCarolyn Cannon
Carolyn Cannon
DADaniel Asher
Daniel Asher
CGChristopher García
Christopher García
RCRobert H Cleveland
Robert H Cleveland
ACAndrew A Colin
Andrew A Colin
Mutations in both alleles of the cystic fibrosis transmembrane conductance regulator gene result in the disease cystic fibrosis, which usually manifests as chronic sinopulmonary disease, pancreatic insufficiency, elevated sodium chloride loss in sweat, infertility among men due to agenesis of the vas deferens and other symptoms including liver disease.